Notes:
The EAFT documented a mild but statistically not significant benefit of aspirin (300mg/day) for prevention of stroke, which was very similar to the degree of aspirin benefit in AFASAK. EAFT also provided a direct comparison of the efficacy of aspirin vs. anticoagulation. The study also confirmed that AF patients with a recent stroke/TIA are at a substantial stroke risk (?%/yr). Furthermore, no patient on anticoagulants in EAFT suffered a documented intracranial hemorrhage.

Back

Contents

Next

Acknowledgments:
The content of this presentation was prepared by Dr. Gregory Albers of the Stanford Stroke Center.